Navigation Links
NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
Date:5/21/2008

NEW YORK, May 21 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced a private placement financing in a total amount of $900,000, which includes a strategic investment from the New England Cryogenic Center, Inc. (NECC), one of the largest full-service cryogenic laboratories in the world.

The financing consists of units priced at $1.20 per unit with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at $1.75 per share.

Robin Smith, MD, MBA, NeoStem's CEO, stated, "We are pleased to announce this new financing, which included investments from both NECC and NeoStem management. These funds will be instrumental in executing on our plan to educate potential clientele about our services, particularly in the Northeast which we believe will be a powerful market. We look forward to working closely with NECC, a strategic partner since October 2007 and located in Massachusetts, to provide extensive new stem cell processing and storage capabilities on the East Coast as well as to embark on a marketing campaign to NECC customers."

On May 9, 2008, NECC was granted a license from the State of New York to process, store and use for research adult hematopoietic stem cells collected from New York residents. NECC's New York licensure will provide NeoStem with greatly expanded storage capacity for one of its largest potential markets and facilitate expanded relationships with leading physician practices.

"We are excited to expand our laboratory offerings to NeoStem in connection with this exciting new project and plan to offer NeoStem's services to our current clients who have elected to store their children's stem cells at the time of birth and those customers who have recovered from cancer," said John Rizza, CEO of New England Cryogenic Center.

Note: The securities sold in the private placement were sold without registration under the Securities Act of 1933, as amended and may not be resold unless subsequently registered under the Act or pursuant to an exemption from registration under the Act.

About NeoStem, Inc.

NeoStem has a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the 'Risk Factors' described in the Company's periodic filings with the Securities and Exchange Commission.

Contact:

NeoStem, Inc.

Robin Smith, Chief Executive Officer

T: 212-584-4180

E: rsmith@neostem.com

http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem to Expand Stem Cell Collection Center Network to Florida
2. NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells
3. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
4. NeoStem to Present at Third Annual Stem Cell Summit in New York City
5. NeoStem Announces NY State License for Adult Stem Cell Collection
6. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
7. Still River Systems Announces Operation of the Worlds Highest Magnetic Field Cyclotron
8. Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
9. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
10. eResearchTechnology Announces Resignation of its CFO
11. Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):